Leukemia - Chronic Lymphocytic - CLL: Latest Research | The Cancer Disappeared

Leukemia - Chronic Lymphocytic - CLL: Latest Research  | The Cancer Disappeared

Best adjuvant (assist) for chemotherapy | 1+1>487% |

Effectively improve chemotherapy effect, treatment, immunity. 

Reduce side effects and recurrence.  

Overview / Relation / Abstract / Role / Principle / Action / Mechanism / Function / Work | 

Leukemia - Chronic Lymphocytic - CLL: Latest Research

Abstract / Summary / Overview of Apoptosis.

Why do cells undergo apoptosis?

The relationship between cancer cells and apoptosis.

Where are the weaknesses and symptoms of cancer cells?

Are cancer cells aggressive?

Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work)

Solamargine's major function mechanism:

Solamargine vs cancer

Best Chemotherapy Adjuvant.  (1+1>478%) 

Effectively improve chemotherapy effect and cure.

When cancer cells are less resistant to drugs, chemotherapy becomes more effective. 



Extract : https://www.cancer.net/cancer-types/

Leukemia - Chronic Lymphocytic - CLL: Latest Research

Approved by the Cancer.Net Editorial Board, 10/2017

You will read about the scientific research being done now to learn more about CLL and how to treat it.

Doctors are working to learn more about CLL, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Most cancer centers are focused on clinical trials aimed at increasing the number of patients who have a complete remission. Always talk with your doctor about the best diagnostic and treatment options for you.

  • New drugs and drug combinations. Researchers are working to find new drugs for CLL. Different combinations of chemotherapy and targeted therapy are also being studied as a way to increase the likelihood that a patient will have a complete remission and live longer. There are many new drugs for CLL, including many new kinase inhibitors, being evaluated in clinical trials for people with recurrent CLL with the hope of testing some of these drugs as initial therapy in the near future.

    • Researchers are also looking at combining ibrutinib with bendamustine, ofatumumab, and rituximab and ibrutinib with fludarabine, cychlophosphamide, and rituximab. Ibrutinib is also being researched along with venetoclax.

    • Idelalisib is being studied in combination with bendamustine, rituximab, and ofatumumab.

    • Xm5574 is a monoclonal antibody also being researched for treatment of CLL.

    • Lenalidomide (Revlimid) is drug commonly used to treat multiple myeloma that is also being looked at as a treatment for CLL, either by itself or in combination with several different drugs for people with recurrent or refractory CLL, as well as for those who have not yet received treatment.

    • Dinaciclib is another drug being researched for CLL.

    • Duvelisib, a type of kinase inhibitor, is also being researched.

  • Genetics. Genetic changes specific to CLL cells are also being evaluated to help predict how well treatment will work, determine the best treatment, and provide information about the cause of the disease. Examples include:

    • Measuring the immunoglobulin mutations of the CLL cells

    • Finding different chromosomal abnormalities in the CLL cells

    • Studying the effects of a protein called ZAP-70, which is found on the surface of the CLL cells

    Some research suggests that these markers can predict the likelihood that the disease may worsen faster. However, there is often a large difference in how well treatment works for patients who seem to have the same genetic markers. It is too early to use these tests to make decisions about when to begin treatment and the type of treatment to use.

  • Palliative care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current CLL treatments to improve patients’ comfort and quality of life.


Abstract / Summary / Overview of Apoptosis. 

Apoptosis.jpg

Overview of apoptosis

•Programmed cell death

•Apoptosis is a form of programmed cell death, or “cellular suicide.”

•Apoptosis is different from necrosis, in which cells die due to injury.

•Apoptosis removes cells during development, eliminates potentially cancerous and virus-infected cells, and maintains balance in the body.


Why do cells undergo apoptosis?

  • Basically, apoptosis is a general and convenient way to remove cells that should no longer be part of the organism.
  • Some cells are abnormal and could hurt the rest of the organism if they survive, such as cells with viral infections or DNA damage.
  • Apoptosis is part of development
  • In many organisms, programmed cell death is a normal part of development.


The relationship between cancer cells and apoptosis

Apoptosis can eliminate infected or cancerous cells.

When a cell’s DNA is damaged, it will typically detect the damage and try to repair it. 

If the damage is beyond repair, the cell will normally send itself into apoptosis, ensuring that it will not pass on its damaged DNA. 

When cells have DNA damage but fail to undergo apoptosis, they may be on the road to cancer.

However, “successful” cancer cells successfully evade the process of apoptosis.

This allows them to divide out of control and accumulate mutations (changes in their DNA).

Apoptosis is key to immune function

Apoptosis also plays an essential role in the development and maintenance of a healthy immune system. 


Where are the weaknesses and symptoms of cancer cells?

The symptoms of cancer cells are in the nucleus.

The nucleus controls the outer cytoplasm, cell composition, cell viability, etc.

DNA mutations also mutate in the nucleus.

Therefore, to treat cancer cells, we must first enter the nucleus.

Let the “regulatory cell gene” mechanism enter the nucleus to regulate


Are cancer cells aggressive?

After the action of Solamargine, the aggressiveness of cancer cells is alleviated.

So after using Solamargine, many patients feel that I am half better.

Although the tumor does not disappear quickly, patients feel that the degree of aggressiveness is reduced.



Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work). 

sr-t100_apoptosis_mechanism005.jpg


Solamargine's major function mechanism:

When Solamargine enter,

Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.

Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.

Reduced drug resistance

When cancer cells are less resistant to drugs, chemotherapy becomes more effective.

Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.


Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?

Chemotherapy_01.jpg



Solamargine vs cancer

cell apoptosis.jpg

Solamargine vs cancer

The picture shows the death of cancer cells.

The black and black parts are cancer cell nuclei.

Even if the nucleus ruptures, the cancer cells will die.

The figure shows that cancer cells can cause death. 

cancer cell apoptosis_01_800.jpg

The figure shows that cancer cells can cause death.

The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.

The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.

The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.



Best Chemotherapy Adjuvant. (1+1>487%) 

Effectively improve chemotherapy effect and treatment.solamargine vs cancer_lung cancer cell.jpg

ANTI-CANCER 

Patent protection in 32 nations. 

A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.

solamargine vs cancer_breast cancer cell_01_800.jpgA comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.

solamargine combined treatment therapy_01_800.jpg

SR-T100 combination therapy with effective result against breast cancer cells.


solamargine combined treatment therapy_03R12_800.jpg

Combination Therapy   |   Research results for lung cancer cells. 

A. Chemotherapy    (100μM), 16% of cancer cell apoptosis. 

B. Alone SM (4.8μM), 28% of cancer cell apoptosis. 

C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.  

D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.  

SM has a clearing effect better than Chemotherapy. 

The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.  

SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).  

SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).  

Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.


justnow_02.jpg

The best solution for cancer cells.

Solamargine Q&A (English)






Older post Newer post